AbbVie Inc (ABBV)vsPrecision BioSciences Inc (DTIL)
ABBV
AbbVie Inc
$261.78
-0.65%
HEALTHCARE · Cap: $454.36B
DTIL
Precision BioSciences Inc
$6.26
+1.29%
HEALTHCARE · Cap: $171.68M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 142805% more annual revenue ($64.39B vs $45.05M). ABBV leads profitability with a 9.8% profit margin vs -117.0%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
DTIL
Avoid33
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.0%
Fair Value
$152.16
Current Price
$261.78
$109.62 premium
Margin of Safety
+69.2%
Fair Value
$13.23
Current Price
$6.26
$6.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Revenue surging 37272.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -58.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.
Bull Case : DTIL
The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.
Bear Case : DTIL
The primary concerns for DTIL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while DTIL is a hypergrowth play — different risk/reward profiles.
DTIL carries more volatility with a beta of 1.25 — expect wider price swings.
DTIL is growing revenue faster at 37272.0% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 33/100) and 10.2% revenue growth. DTIL offers better value entry with a 69.2% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Precision BioSciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?